|
See related Xeloda film-coated tab information |
|
|
|
Manufacturer |
Roche |
|
Distributor |
DKSH |
|
Contents |
Capecitabine |
|
Indications |
Treatment of advanced oesophagogastric cancer, metastatic colorectal cancer, adjuvant treatment of colon cancer (stage III or Dukes' C). Treatment of patients w/ locally advanced or metastatic breast cancer after failure of a taxane & an anthracycline-containing chemotherapy regimen.
Click to view Xeloda detailed prescribing infomation |
|
Dosage |
Monotherapy 2,500 mg/m2/day in 2 divided doses orally for 2 wk followed by 1-wk rest period given as 3-wk cycles. Combination w/ docetaxel: Breast cancer 2,500 mg/m2/day in 2 divided doses for 2 wk followed by 1-wk rest period given as 3-wk cycles. Colon, colorectal & oesophagogastric cancer 1,600-2,000 mg/m2/day in 2 divided doses for 2 wk followed by 1-wk rest period given as 3-wk cycle or 625 mg/m2 bid administered continuously. Adjuvant treatment in stage III colon cancer Total of 6 mth.
Click to view Xeloda detailed prescribing infomation |
|
Overdosage |
View Xeloda overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken with food (Take w/in ½ hr after meals.). |
|
Contraindications |
History of severe & unexpected reactions to fluoropyrimidine therapy or known hypersensitivity to fluorouracil. Known DPD deficiency, severe renal impairment (CrCl <30 mL/min).
Click to view Xeloda detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Xeloda detailed prescribing infomation |
|
Special Precautions |
Pregnancy, lactation, childn <18 yr. Hepatic & renal impairment. Elderly.
Click to view Xeloda detailed prescribing infomation |
|
Adverse Drug Reactions |
Hand & foot syndrome, diarrhoea, nausea, vomiting, stomatitis.
View ADR Monitoring Form |
|
Drug Interactions |
Antacid, sorivudine & analogues, anticoagulants (warfarin), phenytoin, leucovorin, folic acid.
View more drug interactions with Xeloda |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Mechanism of Action |
View Xeloda mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
